We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 1148 for:    L-serine

Determining the Safety of L-serine in ALS

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2015 by Phoenix Neurological Associates, LTD.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01835782
First Posted: April 19, 2013
Last Update Posted: November 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Institute for Ethnomedicine
Information provided by (Responsible Party):
Phoenix Neurological Associates, LTD
  Purpose
The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.

Condition Intervention Phase
Amyotrophic Lateral Sclerosis (ALS) Drug: L-Serine Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Determining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses.

Resource links provided by NLM:


Further study details as provided by Phoenix Neurological Associates, LTD:

Primary Outcome Measures:
  • Safety of L-Serine [ Time Frame: 1-6 months ]
    Determining the safety of L-Serine given at 0.5 gm twice daily (BID), 2.5gm BID, 7.5g BID or 15 grams BID for six months by assessing the total number of adverse events (AE)during treatment


Secondary Outcome Measures:
  • Measure levels of β-Methylamino-L-alanine (BMAA) in blood, urine and Cerebrospinal fluid (CSF) to determine if there is a decline in levels over the course of treatment [ Time Frame: 1-6 months ]

Estimated Enrollment: 20
Study Start Date: January 2013
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 2.5 grams BID
5 Patients will be evenly randomized into this group
Drug: L-Serine
Active Comparator: .5 grams BID
5 Patients will be evenly randomized into this group
Drug: L-Serine
Active Comparator: 7.5 grams BID
5 Patients will be evenly randomized into this group
Drug: L-Serine
Active Comparator: 15 grams BID
5 Patients will be evenly randomized into this group
Drug: L-Serine

Detailed Description:
Previous studies into the Guamian ALS-Parkinson's Dementia complex has identified β-methylamino-L-alanine (BMAA), as a potential neurotoxin responsible for this disease. BMAA is a non-essential amino acid and is produced by a cyanobacterium which is present in all ecosystems. Subsequently several groups have identified high concentrations of BMAA in brain tissues of patients from North America and Europe with several neurodegenerative diseases including ALS, Parkinson's Disease and Alzheimer's Diseases. It has been hypothesized that chronic intake of BMAA in the diet leads to mis-incorporation of the amino acid into brain proteins, where it produces slow neuronal damage and recent evidence has shown that BMAA is mis-incorporated into proteins in neuronal cell lines via seryl tRNA synthetase, thereby producing protein mis-folding and protein aggregates, leading to cell death. It has been demonstrated in mammalian neuronal cell cultures that exogenous L-serine could prevent the BMAA neurotoxin from being mis-incorporated into proteins, thereby preventing cell death and that very high doses of L-serine may compete with the transport of a number of non-essential amino acids across the blood-brain barrier via the y+ transporter. These findings have led us to believe that high doses of L-serine could possibly stop the mis-incorporation of BMAA into brain proteins which in turn would slow or even abate the progression of ALS. This study will determine the safety of different doses of L-serine given to ALS subjects at 0.5 gm twice daily (BID), 2.5gm BID, 7.5g BID or 15 grams BID for six months.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-85
  2. Male or Female
  3. Clinically diagnosed with probable or definite ALS based on El Escorial criteria
  4. ALSFRS-R > 25
  5. Able to provide informed consent to and comply with all medical procedures

Exclusion Criteria:

  1. Outside age range of 18-85
  2. Subjects with forced vital capacity (FVC) below 60%
  3. Evidence of any motor neuron disease for over 3 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01835782


Locations
United States, Arizona
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
United States, California
Forbes Norris MDA/ALS Research Center
San Francisco, California, United States, 94115
Sponsors and Collaborators
Phoenix Neurological Associates, LTD
Institute for Ethnomedicine
Investigators
Principal Investigator: Todd D Levine, MD Phoenix Neurological Associates, LTD
  More Information

Responsible Party: Phoenix Neurological Associates, LTD
ClinicalTrials.gov Identifier: NCT01835782     History of Changes
Other Study ID Numbers: L-Serine2013
IND ( Other Identifier: 116871 )
First Submitted: March 27, 2013
First Posted: April 19, 2013
Last Update Posted: November 6, 2017
Last Verified: July 2015

Keywords provided by Phoenix Neurological Associates, LTD:
ALS
L-Serine
BMAA

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases